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Abstract: Vulvar cancer is uncommon and may be confused with genital condylomata. 
We report two cases of middle-aged women presenting with exophytic vulvar tumors of 
the midline for which diagnosis of a vulvar squamous cell carcinoma was confirmed by 
histopathology. Risk factors, staging, and treatment options are discussed.
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Introduction
Vulvar carcinomas are rare malignancies, and squamous cell carcinoma (SCC) of the 
vulva account for about 80% of such cases.1 Vulvar intraepithelial neoplasia and vulvar 
Bowen’s disease are considered as possible precursors of vulvar SCC.2
There are two major ways vulvar SCC can develop: (a) 8.6%–40% of cases emerge 
due to infection with carcinogenic subtypes of human papilloma virus (HPV) and 
(b) 60%–70% of tumors are not related to HPV .3–5 Among HPV types, HPV-16 seems 
to be the most commonly isolated in vulvar carcinomas with HPV-11 and HPV-6 
being less common.4 Vulvar SCC with a warty surface has been strongly linked with 
HPV-33, HPV-45, HPV-52, HPV-18, and HPV-16.6
Several conditions of either autoimmune or infectious origin and miscellaneous 
disorders have been associated with development of vulvar SCC, such as Hailey–Hailey 
disease,7 pemphigus vulgaris and systemic lupus erythematosus,8 lichen sclerosus and 
Langerhans cell histiocytosis,9 Crohn’s disease,10 Fanconi’s anemia,11 and infection 
with human immunodeficiency virus (HIV).12
In women aged less than 40 years, vulvar SCC is extremely rare.13 The availability 
of HPV vaccination may lead to a reduction in HPV-associated vulvar SCC.4 SCC is 
an important clinical and histological differential diagnosis in anogenital condylomata 
accuminata.14 However, SCC may be misdiagnosed as condyloma. We report two 
middle-aged females presenting with condyloma-like vulvar midline SSC.
Case reports
Case 1
A 41-year-old woman was seen in consultation for the combination of an asymptomatic 
hyperpigmented plaque type vulvar lesion on the right side and a painful exophytic 
nodule of the contralateral site arising from a larger flat leucoplakic lesion (Figure 1). 
The lesions were noted for .1 year (plaque) and 3 months (nodule). She was obese 
and was on treatment for insulin-dependent diabetes mellitus.
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The hyperpigmented lesion was flat, macular, and had 
well-defined borders. The nodule on the left side of the vulva 
was about 4 cm in diameter, was pedunculated, had a firm 
consistency, was covered in whitish film-like material and 
exhibited a verrucous whitish cover. Two diagnostic biopsies 
were taken from each side. Histopathological examination 
of the nodule revealed an epithelial proliferation with 
the formation of horn pearls, keratinocytes with nuclear 
polymorphism, and increased mitotic activity (Figure 2). 
The basement membrane was not well-maintained but deeper 
infiltration was absent. The diagnosis was squamous cell 
carcinoma, Broder grade II. The other lesion was diagnosed 
as pigmented Bowen’s disease with pagetoid growth of 
enlarged intraepithelial keratinocytes developing into SCC. 
The tumor was staged as stage II according to International 
Federation of Gynecology and Obstetrics staging guidelines 
and T2N0M0 according to Union for International Cancer 
Control guidelines (Table 1).15 The patient was referred to 
the gynecologist for vulvectomy.
Case 2
A 44-year-old female presented with asymptomatic 
condyloma-like protrusions affecting labia majora and 
perineum and she noted . 2 years of slow enlargement 
(Figure 3). She was a smoker for .20 package-years but her 
medical history was unremarkable. The tumor presented as firm 
mass infiltrating the deeper structures. Magnetic resonance 
imaging revealed a deep subcutaneous neoplasia, extruding 
vagina and anus, and penetrating urogenital diaphragm 
including the musculus peroneus profundus measuring 
33 × 43 × 42 mm. Lymph node metastasis was observed in the 
right groin. Histopathology revealed SSC, Broder grade III. 
Figure 1 Warty exophytic SCC of the vulva (case 1).
Abbreviation: SCC, squamous cell carcinoma.
Table 1 Revised FIGO classification of vulvar carcinoma15
  IA      Tumor confined to the vulva or perineum, #2 cm in size with 
stromal invasion # 1 mm, negative nodes
   IB     Tumor confined to the vulva or perineum, .2 cm in size or with 
stromal invasion . 1 mm, negative nodes
    II     Tumor of any size with adjacent spread (1/3 lower urethra, 1/3 
lower vagina, anus), negative nodes
IIIA  Tumor of any size with positive inguinofemoral lymph nodes
     (i)  1 lymph node metastasis greater than or equal to 5 mm
    (ii)  1–2 lymph node metastasis(es) of less than 5 mm
IIIB    (i)  2 or more lymph nodes metastases greater than or equal to 5 mm
    (ii)  3 or more lymph nodes metastases less than 5 mm
IIIC  Positive node(s) with extracapsular spread
IVA (i)   Tumor invades other regional structures (2/3 upper urethra, 2/3 upper   
vagina), bladder mucosa, rectal mucosa, or fixed to pelvic bone
    (ii)  Fixed or ulcerated inguinofemoral lymph nodes
IVB  Any distant metastasis including pelvic lymph nodes
Abbreviation:  reproduced,  with  permission  granted  by  the  International 
Federation of Gynecology and Obstetrics (FIGO), from:Pecorelli, S. revised FIGO 
staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 
2009;105(2):103–104.
Figure  2  Histopathology  of  the  vulvar  squamous  cell  carcinoma  (case  1):   
(A) Overview with epitheloid strands, cellular and nuclear atypias and formation of 
horn pearls (×4). (B) Multiple mitoses (×40). Hematoxylin-eosin stains.
The tumor was staged as stage IIIA according to International 
Federation of Gynecology and Obstetrics staging guidelines 
and T3N1M0 according to Union for International Cancer 
Control guidelines (Table 1).15 Surgery was performed for 
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transmitted diseases, and cigarette smoking. Type 2 affects 
elderly women. SCC is seen more often in type 2 vulvar 
cancer.16 Our patients, however, belonged to the age-group 
of type 1 and both had SCC Broder grades II and III.
Vulvar SCC may be completely asymptomatic. When 
symptoms are present, the most common include pruritus 
vulvae, vulvar bleeding or pain, swelling, or vaginal dis-
charge.16,17 Often, the patient does not complain due to 
cultural reasons, the so-called “culture of silence”, due 
to embarrassment, or for economic reasons. Vulvar SCC 
may be confused with condyloma14 and therefore may be 
  inadequately treated by various modalities. Important dif-
ferential diagnoses of vulvar SCC are listed in Table 2.
Figure 3 Condyloma-like exophytic growth of vulvar squamous cell carcinoma (case 2).
Figure 4 Operation situs after debulking surgery (case 2).
tumor debulking (Figure 4). The patient was referred to the 
gynecologist for combined chemoradiotherapy.
Discussion
Vulvar cancer can be differentiated as two types: type 1 is 
seen in patients younger than 65 years old with frequent 
detection of HPV DNA and a strong association to pre-
existing condyloma, vulvar intraepithelial neoplasia, sexually 
Table 2 Differential diagnoses of vulvar SCC
Nonmalignant
  Vestibular papillomatosis
  Condylomata accuminata
  Condylomata lata
  Epidermal nevus
  Epidermolytic akanthoma
  Lipoma
  Lichen sclerosus
  Leiomyoma
  Lymphangioma
  Fibroadenoma
  Genital herpes simplex infection
  Hidradenoma papilliferum
  Angiofibrolipom
  Actinomycosis
  rheumatoid nodule
  Schistosomiasis
  Syringoma
  Verruciform xanthoma
  Pinworm infestation
  Benign phylloides tumor
  Lymphedematous pseudotumor
Malignant
  Paget’s disease
  Adenocarcinoma
  Angiomyxoma
  Basal cell carcinoma
  Verrucous carcinoma
  Bartholoni’s gland carcinoma
  Merkel cell carcinoma
  Melanoma
  Malignant schwannoma
  Malignant fibrous histiocytoma
  Malignant giant cell tumor
  Myoepithelial carcinoma
  Ductal carcinoma
  Malignant phyllpoides tumor
  Sarcomas
  Lymphomas (including mycosis fungoides)
  Metastases
Abbreviation: SCC, squamous cell carcinoma.
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The 5-year survival rates for vulvar SCC have been 
estimated as 41% for India,18 68% for South Korea,19 and 86% 
in the United States.1 The most important negative prognostic 
factor for vulvar SCC is the inguinofemoral lymph node 
status at the time of initial diagnosis.20 Surgery remains the 
cornerstone of therapy. Individualized vulvectomy should be 
accompanied by groin lymph node dissection for tumors with 
a diameter of at least 2 cm and those invading 1 mm or deeper. 
Medially located tumors may spread bilaterally.21,22 Surgery, 
tumor stage, and stromal invasion of less than 9 mm were the 
most dominant predictors for relapse-free survival in a recent 
study in Italy.23 The distance of the surgical margins is critical 
for the prevention of local relapses. In a study analyzing 
93 patients with vulvar carcinoma, a margin of more than 
8 mm did not improve recurrence rate.24 In advanced 
cases, neoadjuvant chemotherapy is a beneficial option if 
surgery can be performed thereafter.25 The combination of 
chemotherapy and radiation is an option for patients where 
surgery is impossible.26,27 In our cases, vulvectomy is planned 
for case 1 and combined chemoradiotherapy after debulking 
surgery is planned for case 2.
In conclusion, it is important for dermatologists to be 
aware of vulvar SCC and consider this malignancy when 
dealing with large vulvar condylomas. Early recognition 
with reference to treatment by gynecologists, oncologists, 
and radiologists helps to improve outcome.
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